Navigation Links
Researchers develop new tool for gene delivery
Date:1/27/2010

BOSTON (January 27, 2010) Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have developed a new tool for gene therapy that significantly increases gene delivery to cells in the retina compared to other carriers and DNA alone, according to a study published in the January issue of The Journal of Gene Medicine. The tool, a peptide called PEG-POD, provides a vehicle for therapeutic genes and may help researchers develop therapies for degenerative eye disorders such as retinitis pigmentosa and age-related macular degeneration.

"For the first time, we have demonstrated an efficient way to transfer DNA into cells without using a virus, currently the most common means of DNA delivery. Many non-viral vectors for gene therapy have been developed but few, if any, work in post-mitotic tissues such as the retina and brain. Identifying effective carriers like PEG-POD brings us closer to gene therapy to protect the retinal cells from degeneration," said senior author Rajendra Kumar-Singh, PhD, associate professor of ophthalmology and adjunct associate professor of neuroscience at Tufts University School of Medicine (TUSM) and member of the genetics; neuroscience; and cell, molecular, and developmental biology program faculties at the Sackler School of Graduate Biomedical Sciences at Tufts.

Safe and effective delivery of therapeutic genes has been a major obstacle in gene therapy research. Deactivated viruses have frequently been used, but concerns about the safety of this method have left scientists seeking new ways to get therapeutic genes into cells.

"We think the level of gene expression seen with PEG-POD may be enough to protect the retina from degeneration, slowing the progression of eye disorders and we have preliminary evidence that this is indeed the case," said co-author Siobhan Cashman, PhD, research assistant professor in the department of ophthalmology at TUSM and member of Kumar-Singh's lab.

"What makes PEG-POD especially promising is that it will likely have applications beyond the retina. Because PEG-POD protects DNA from damage in the bloodstream, it may pave the way for gene therapy treatments that can be administered through an IV and directed to many other parts of the body," said Kumar-Singh.

Kumar-Singh and colleagues used an in vivo model to compare the effectiveness of PEG-POD with two other carriers (PEG-TAT and PEG-CK30) and a control (injections of DNA alone).

"Gene expression in specimens injected with PEG-POD was 215 times greater than the control. While all three carriers delivered DNA to the retinal cells, PEG-POD was by far the most effective," said first author Sarah Parker Read, an MD/PhD candidate at TUSM and Sackler and member of Kumar-Singh's lab.

Age-related macular degeneration, which results in a loss of sharp, central vision, is the number one cause of vision loss in Americans age 60 and older. Retinitis pigmentosa, an inherited condition resulting in retinal damage, affects approximately 1 in 4,000 individuals in the United States.


'/>"/>

Contact: Siobhan Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. Researchers at Meharry Medical College Find Green Tea Extract Showing Promise for Treatment of Uterine Fibroids
2. Researchers welcome new multiple sclerosis drug
3. Barrow researchers receive more than $2 million in NIH grants for nicotine studies
4. Researchers discover method to objectively identify PTSD
5. Researchers find a treatment for deadly brain tumor
6. Researchers find new insights into inherited retinal disease
7. Pitt researchers raise concern over frequency of surveillance colonoscopy
8. Stress triggers tumor formation, Yale researchers find
9. Johns Hopkins researchers say vaccine appears to mop up leukemia cells Gleevec leaves behind
10. St. Johns wort not helpful treatment for irritable bowel syndrome, Mayo Clinic researchers say
11. Young hunters most likely to be injured using tree stands, say UAB researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Livionex, Inc., ... results of a double blind clinical study for its dental gel that shows significant ... national brand of toothpaste containing triclosan. The study was conducted at the Beckman Laser ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians ... Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, ... the announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra ...
(Date:1/17/2017)... ... January 17, 2017 , ... Lynx Technology Partners ... top US security companies for consecutive years, today announced the appointment of four ... independent board nomination process to a close and positions Lynx for even faster ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, FloSports , a global leader ... new agreement as part of a long-term extension of their media partnership. The partnership, ... of some of the sport’s premier events exclusively on FloWrestling.com as well as usage ...
(Date:1/16/2017)... (PRWEB) , ... January 17, 2017 , ... ... Au Bon Pain, an internationally recognized leader in the fast-casual category, announces a ... such as the Good Egg Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... Jan. 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... , today announced that it has implemented ... of the Zimmer Biomet management team. Effective January ... assume the position of President, Americas and join ... previously served as Zimmer Biomet,s Vice President of ...
(Date:1/17/2017)... Jan. 17, 2017 Tempus, a technology ... and University Hospitals Seidman Cancer Center have joined ... genomic data, advanced molecular analysis and clinical decision ... and healthcare providers. As part ... and transcriptomic sequencing and analysis for ovarian and ...
Breaking Medicine Technology: